The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2008.
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | eng |
| Published: |
Massachusetts Institute of Technology
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1721.1/44321 |
| _version_ | 1826211084834439168 |
|---|---|
| author | Pasanek, David M |
| author2 | Kristala Prather and Donald B. Rosenfield. |
| author_facet | Kristala Prather and Donald B. Rosenfield. Pasanek, David M |
| author_sort | Pasanek, David M |
| collection | MIT |
| description | Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2008. |
| first_indexed | 2024-09-23T15:00:37Z |
| format | Thesis |
| id | mit-1721.1/44321 |
| institution | Massachusetts Institute of Technology |
| language | eng |
| last_indexed | 2024-09-23T15:00:37Z |
| publishDate | 2009 |
| publisher | Massachusetts Institute of Technology |
| record_format | dspace |
| spelling | mit-1721.1/443212022-01-28T18:30:39Z The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics Pasanek, David M Kristala Prather and Donald B. Rosenfield. Leaders for Manufacturing Program. Leaders for Manufacturing Program at MIT Massachusetts Institute of Technology. Department of Chemical Engineering Sloan School of Management Sloan School of Management. Chemical Engineering. Leaders for Manufacturing Program. Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2008. Includes bibliographical references (p. [80]-87). The Amgen Rhode Island facility is dedicated to the production of the biological bulk drug substance (BDS) for Enbrel® (etanercept), which blocks the action of one's immune system, helping to treat immune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. A productivity process improvement is currently being implemented that will change the manufacturing capacity of the production process at each of the three separately owned manufacturing facilities for Enbrel® BDS. Given that the Amgen Rhode Island facility currently only produces Enbrel® BDS, the Rhode Island facility has the largest capacity of all the BDS manufacturers, and that Enbrel®'s initial patent expires at the end of 2012; product sourcing is a major concern for both the Rhode Island site and the Enbrel® supply network.As biopharmaceutical companies shift their focus more toward more efficient production operations, issues such as diminishing productivity in drug development and the impact of an emerging follow-on biologics market are becoming critical factors in determining a company's long-term growth and sourcing strategy. This research examines both the qualitative and quantitative components that go into strategic sourcing decisions that are made by innovative biological therapeutic producers. This thesis develops a methodology and framework for strategic sourcing decisions and guidelines for selecting, implementing, and managing relationships within a biotechnological manufacturing network of separately owned facilities as applied to the Enbrel® BDS case study. by David M. Pasanek. S.M. M.B.A. 2009-01-30T16:32:26Z 2009-01-30T16:32:26Z 2008 2008 Thesis http://hdl.handle.net/1721.1/44321 275174793 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 87 p. application/pdf Massachusetts Institute of Technology |
| spellingShingle | Sloan School of Management. Chemical Engineering. Leaders for Manufacturing Program. Pasanek, David M The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title | The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title_full | The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title_fullStr | The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title_full_unstemmed | The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title_short | The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologics |
| title_sort | conclusion of a biologic s lifecycle manufacturing sourcing strategies on the eve of follow on biologics |
| topic | Sloan School of Management. Chemical Engineering. Leaders for Manufacturing Program. |
| url | http://hdl.handle.net/1721.1/44321 |
| work_keys_str_mv | AT pasanekdavidm theconclusionofabiologicslifecyclemanufacturingsourcingstrategiesontheeveoffollowonbiologics AT pasanekdavidm conclusionofabiologicslifecyclemanufacturingsourcingstrategiesontheeveoffollowonbiologics |